Literature DB >> 10915929

Synthesis, pharmacokinetics and anticonvulsant activity of 7-chlorokynurenic acid prodrugs.

F P Bonina1, L Arenare, R Ippolito, G Boatto, G Battaglia, V Bruno, P de Caprariis.   

Abstract

7-Chlorokynurenic acid 1 is a potent glycine-N-methyl-D-aspartate (NMDA) receptor antagonist, but it shows weak activity after systemic administration. In order to overcome the Blood-brain barrier (BBB), we synthetized three new esters 2-4 of 1 obtained by chemical conjugation with essential nutrients such as glucose and galactose, that are actively transported across the BBB. These compounds were assayed to evaluate their in vitro chemical and enzymatic hydrolysis. In addition the prodrugs 2-4 were tested for their ability to protect mice against NMDA-induced seizures after systemic administration. All the prodrugs 2-4 appeared moderately stable in pH 7.4 buffered solution and were susceptible to in vitro enzymatic hydrolysis. Intraperitoneal administration of either esters 2 or 4 was highly protective against seizures induced by NMDA in mice, with the latter prodrug showing the highest anticonvulsive activity. In addition, ester 4 undergoes a time-dependent extracellular hydrolysis into 1 when applied to mixed cultures of mouse cortical cells, a model that reproduces in vitro the cellular milieu encountered by the prodrugs once they penetrate the brain parenchyma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10915929     DOI: 10.1016/s0378-5173(00)00421-x

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  11 in total

Review 1.  Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery.

Authors:  Simon G Patching
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

Review 2.  Getting into the brain: approaches to enhance brain drug delivery.

Authors:  Mayur M Patel; Bhoomika R Goyal; Shraddha V Bhadada; Jay S Bhatt; Avani F Amin
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 3.  Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain.

Authors:  Mayur M Patel; Bhoomika M Patel
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 4.  Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics.

Authors:  Magdalena Markowicz-Piasecka; Agata Markiewicz; Patrycja Darłak; Joanna Sikora; Santosh Kumar Adla; Sreelatha Bagina; Kristiina M Huttunen
Journal:  Neurotherapeutics       Date:  2022-04-07       Impact factor: 6.088

5.  Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting.

Authors:  Fulan Xie; Nian Yao; Yao Qin; Qianyu Zhang; Huali Chen; Mingqing Yuan; Jie Tang; Xiankun Li; Wei Fan; Qiang Zhang; Yong Wu; Li Hai; Qin He
Journal:  Int J Nanomedicine       Date:  2012-01-06

Review 6.  Targeting Transporters for Drug Delivery to the Brain: Can We Do Better?

Authors:  Elena Puris; Gert Fricker; Mikko Gynther
Journal:  Pharm Res       Date:  2022-03-31       Impact factor: 4.580

Review 7.  KYNA Derivatives with Modified Skeleton; Hydroxyquinolines with Potential Neuroprotective Effect.

Authors:  Bálint Lőrinczi; István Szatmári
Journal:  Int J Mol Sci       Date:  2021-11-03       Impact factor: 5.923

8.  Synthetic- and DFT modelling studies on regioselective modified Mannich reactions of hydroxy-KYNA derivatives.

Authors:  Bálint Lőrinczi; Antal Csámpai; Ferenc Fülöp; István Szatmári
Journal:  RSC Adv       Date:  2020-12-24       Impact factor: 3.361

9.  Synthesis of Indole-Coupled KYNA Derivatives via C-N Bond Cleavage of Mannich Bases.

Authors:  Bálint Lőrinczi; Péter Simon; István Szatmári
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

Review 10.  Progress in drug delivery to the central nervous system by the prodrug approach.

Authors:  Barbara Pavan; Alessandro Dalpiaz; Nunzia Ciliberti; Carla Biondi; Stefano Manfredini; Silvia Vertuani
Journal:  Molecules       Date:  2008-05-01       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.